nach oben

Archives of Gynecology and Obstetrics

Erschienen in:

01.03.2010 | Original Article

Analysis of the distribution shift of detected aneuploidies by age independent first trimester screening

verfasst von: Peter Schmidt, C. Hörmansdörfer, M. Golatta, A. Scharf

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 3/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

First trimester screening (FTS) became standard in non-invasive testing for chromosomal abnormalities in early pregnancy. The individual risk is calculated on the basis of a general background risk, which refers to the maternal age. A new method, Advanced Firsttrimester Screening (AFS) excludes the background risk in its algorithm. This study had the aim to analyze how the detection of aneuploidies is influenced by the in- or exclusion of the maternal age in the risk calculation.

Materials and methods

The data of 15,228 first trimester screenings were recalculated with FTS and AFS. The study cohort was divided by age into nine groups and the numbers of detected cases were recorded according to the groups of age.

Results

Of 129 detected aneuploidies 90% got the same test results, disregarding whether risk assessment is performed including maternal age or not. FTS detected five aneuploidies at age 35 or older that were not recorded by AFS. AFS detected six aneuploidies that were not detected by FTS. Out of these, the oldest mother was 32 years old.

Discussion

When excluding the maternal age from risk calculation, the detection of aneuploidies showed a shift from older to younger women. Overall, the detection rate did not change significantly. However, the false positive rate was 25% lower with the exclusion of maternal age.

Krampl E, Wertaschnigg D, Husslein P (2002) Down-syndrom-screening im ersten Trimenon. Geburtshilfe Frauenheilkd 62(9):843–848. doi:10.1055/s-2002-33894 CrossRef

Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A, Hogge WA, Wilson RD, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill L, Gagnon A, Hallahan T, Jackson L (2003) First-trimester screening for trisomy-21 and 18. N Engl J Med 349:1405–1413. doi:10.1056/NEJMoa025273 CrossRefPubMed

Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH (1999) Maternal age and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 14:167–170. doi:10.1046/j.1469-0705.1999.13030167.x CrossRef

Nicolaides KH, Sebire N, Snijders RJM (1999) Die Ultraschalluntersuchung der. Schwangerschaftswoche. Pathenon Publishing, Birmingham, pp 11–14

Snijders RJM, Noble P, Sebire N, Souka A, Nicolaides KH (1998) UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10–14 weeks of gestation. Lancet 351:343–346. doi:10.1016/S0140-6736(97)11280-6 CrossRef

Spencer K, Souter V, Tul N, Snijders RJM, Nicolaides KH (1999) A Screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin an pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 13:231–237. doi:10.1046/j.1469-0705.1999.13040231.x CrossRefPubMed

Wald NJ, Hackshaw AK (1997) Combining ultrasound and biochemistry in first-trimester screening for Down’s syndrome. Prenat Diagn 17:821. doi:10.1002/(SICI)1097-0223(199709)17:9<821::AID-PD154>3.0.CO;2-5 CrossRefPubMed

Schmidt P, Pruggmayer M, Steinborn A, Schippert C, Staboulidou I, Hillemanns P, Scharf A (2007) Are nuchal translucency, pregnancy associated plasma protein-A or free-ß-human chorionic gonadotropin depending on maternal age? A multicenter study of 8116 pregnancies. Arch Gynecol Obstet 276(3):259–262. doi:10.1007/s00404-007-0342-4 CrossRefPubMed

Schmidt P, Scharf A (2006) Advanced Firsttrimester screening—a critical review of the fundamental studies and suggestions for improvement. Geburtshilfe Frauenheilkd 67:S1–S183

10.

Schmidt P, Rom J, Maul H, Vaske B, Hillemanns P, Scharf A (2007) Advanced first trimester screening (AFS): an improved test strategy for the individual risk assessment of fetal aneuploidies and malformations. Arch Gynecol Obstet 276(2):159–166. doi:10.1007/s00404-007-0324-6 CrossRefPubMed

11.

Hörmansdörfer C, Schmidt P, Hillemanns P, Scharf A (2007) Die pränatale Detektion der Triosomie 13, 18 und 21: Vergleich des Advanced Firsttrimester Screenings (AFS)^® mit dem Ersttrimester-Screening nach Nicolaides. Z Geburtshilfe Neonatol 211:243–249. doi:10.1055/s-2007-981361 CrossRefPubMed

12.

Schmidt P, Hörmansdörfer C, Pruggmayer M, Schütte C, Neumann A, Gerritzen A, Vaske B, Hillemanns P, Scharf A (2008) Improved prenatal aneuploidy screening using the novel ‘Advanced First Trimester Screening’ algorithm—a multicenter study of 10,017 pregnancies. J Clin Ultrasound 36(7):397–402. doi:10.1002/jcu.20509 CrossRefPubMed

13.

Schmidt P, Hörmansdörfer C, Hillemanns P, Scharf A (2007) Presentation of a novel computer software for the Advanced Firsttrimester Screening. Geburtshilfe Frauenheilkd 68:899

14.

Palomaki GE, Haddow JE (1987) Maternal serum alpha-fetoprotein, age, and Down syndrome risk. Am J Obstet Gynecol 156(2):460–463PubMed

15.

Scharf A, Schmidt P, Seppelt M, Maul H, Wüstemann M, Sohn C (2003) Comparison of risk calculation for trisomy 21 by Nicolaides with a novel software: retrospective analysis of 744 cases. Geburtshilfe Frauenheilkd 63:148–152. doi:10.1055/s-2003-37465

16.

Schmidt P, Staboulidou I, Soergel P, Wüstemann M, Hillemanns P, Scharf A (2007) Comparison of Nicolaides’ risk evaluation for Down’s syndrome with a novel software: an analysis of 1463 cases. Arch Gynecol Obstet 275(6):469–474. doi:10.1007/s00404-006-0288-y CrossRefPubMed

17.

Schmidt P, Scharf A, Hörmansdörfer C, Elsässer M, Hillemanns P (2007) Different calculation methods for first trimester screening. Frauenarzt 48(11):1089–1092

18.

Snijders RJM, Sebire NJ, Cuckle H, Nicolaides KH (1995) Maternal age and gestational age-specific risks for chromosomal defects. Fetal Diagn Ther 10:356–367CrossRefPubMed

19.

Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D’Alton ME (2005) First- and second-trimester evaluation of risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 353(19):2001–2011CrossRefPubMed

20.

Bindra R, Heath V, Liao A, Spencer K, Nicolaides KH (2002) One-stop clinic for assessment of risk for trisomy 21 at 11–14 weeks: a prospective study of 15 030 pregnancies. Ultrasound Obstet Gynecol 20(3):219–225. doi:10.1046/j.1469-0705.2002.00808.x CrossRefPubMed

21.

O’Leary P, Breheny N, Dickinson JE, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R (2006) First-trimester combined screening for Down syndrome and other fetal anomalies. Obstet Gynecol 107(4):869–876PubMed

22.

Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O (2005) Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first trimester screening. Ultrasound Obstet Gynecol 25(3):221–226. doi:10.1002/uog.1860 CrossRefPubMed

23.

Crossley JA, Aitken DA, Cameron AD, McBride E, Connor JM (2002) Combined ultrasound and biochemical screening for Down’s syndrome in the first trimester: a Scottish multicentre stuy. BJOG 109(6):667–676. doi:10.1111/j.1471-0528.2002.01394.x CrossRefPubMed

24.

Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH (2003) Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 110(3):281–286. doi:10.1046/j.1471-0528.2003.02246.x CrossRefPubMed

25.

Hadlow NC, Hewitt BG, Dickinson JE, Jacoby P, Bower C (2005) Community-based screening for Down’s Syndrome in the first trimester using ultrasound and maternal serum biochemistry. BJOG 112(11):1561–1564. doi:10.1111/j.1471-0528.2005.00722.x CrossRefPubMed

26.

Wapner R, Thom E, Simpson JL et al (2003) First-trimester screening for trisomies 21 and 18. N Engl J Med 349(15):1405–1413. doi:10.1056/NEJMoa025273 CrossRefPubMed

27.

Wojdemann KR, Shalmi AC, Christiansen M et al (2005) Improved first-trimester Down syndrome screening performance by lowering the false-positive rate: a prospective study of 9941 low-risk women. Ultrasound Obstet Gynecol 25:227–233. doi:10.1002/uog.1834 CrossRefPubMed

28.

Muller F, Benattar C, Audibert F, Roussel N, Dreux S, Cuckle H (2003) First-trimester screening for Down syndrome in France combining fetal nuchal translucy measurement and biochemical markers. Prenat Diagn 23(10):833–836. doi:10.1002/pd.700 CrossRefPubMed

29.

Stenhouse EJ, Crossley JA, Aitken DA, Brogan K, Cameron AD, Connor JM (2004) First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice. Prenat Diagn 24:774–780. doi:10.1002/pd.980 CrossRefPubMed

30.

Schuchter K, Hafner E, Stangl G, Metzenbauer M, Hofinger D, Philipp K (2002) The first trimester ‘combined test’ for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat Diagn 22(3):211–215. doi:10.1002/pd.288 CrossRefPubMed

31.

Perni SC, Predanic M, Kalish RB, Chervenak FA, Chasen ST (2006) Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol 194(1):127–130. doi:10.1016/j.ajog.2005.06.068 CrossRefPubMed

32.

Schielen PC, van Leeuwen-Spruijt M, Belmouden I, Elvers LH, Jonker M, Loeber JG (2006) Multi-centre first-trimester screening for Down syndrome in the Netherlands in routine clinical practice. Prenat Diagn 26(8):711–718. doi:10.1002/pd.1486 CrossRefPubMed

33.

von Kaisenberg CS, Gasiorek-Wiens A, Bielicki M, Bahlmann F, Meyberg H, Kossakiewicz A et al (2002) Screening for trisomy 21 by maternal age, fetal nuchal translucency and maternal serum biochemistry at 11–14 weeks: a German multicenter study. J Matern Fetal Neonatal Med 12(2):89–94. doi:10.1080/713605621

34.

Soergel P, Pruggmayer M, Schwerdtfeger R, Mühlhaus K, Scharf A (2006) Screening for Trisomy 21 with Maternal Age, Fetal Nuchal Translucency and Maternal Serum Biochemistry at 11–14 Weeks: A Regional Experience from Germany. Fetal Diagn Ther 21(3):264–268. doi:10.1159/000091353 CrossRefPubMed

35.

Scott F, Peters H, Bonifacio M et al (2004) Prospective evaluation of a first trimester screening program for Down syndrome and other chromosomal abnormalities using maternal age, nuchal translucency and biochemistry in an Australian population. Aust N Z J Obstet Gynaecol 44(3):205–209. doi:10.1111/j.1479-828X.2004.00205.x CrossRefPubMed

36.

Schmidt P (2009) Non-invasive screening methods for chromosomal aberrations in early pregnancy. In: Columbus (ed) Aneuploidy: common forms, mechanisms and detection. Nova Publishing, Hauppauge (accepted)

Titel: Analysis of the distribution shift of detected aneuploidies by age independent first trimester screening
verfasst von: Peter Schmidt
C. Hörmansdörfer
M. Golatta
A. Scharf
Publikationsdatum: 01.03.2010
Verlag: Springer-Verlag
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 3/2010
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-009-1137-6

Neu im Fachgebiet Gynäkologie und Geburtshilfe

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Analysis of the distribution shift of detected aneuploidies by age independent first trimester screening

Abstract

Introduction

Materials and methods

Results

Discussion

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hochrisiko-Eingriffe für postoperative Übelkeit

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Gynäkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2010

The relation between the presence of a giant primary ovarian leiomyoma and the occurrence of epilepsy as a paraneoplastic syndrome

Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review

Pregnancy after living-related liver transplantation associated with severe preeclampsia and a review of the literature

Oral contraceptives alone and with spironolactone increase sCD40 ligand in PCOS patients

The effect of ovarian cyst aspiration on IVF treatment with GnRH

Acute pancreatitis associated with hypertriglyceridemia: a life-threatening complication

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hochrisiko-Eingriffe für postoperative Übelkeit

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Gynäkologie